Trius raising funds for antibacterial work; Vanda touts preliminary data;

@FierceBiotech: A future threat to Provenge? Researchers target multiple tumors (prostate, lung, others) in new cancer vaccine study. Article | Follow @FierceBiotech

@JohnCFierce: Interesting note: Abingworth, a major Avila investor, also cashed out of Intellikine ($310M) in Dec. For VCs, M&A is key this year. | Follow @JohnCFierce

@MarkHFierce: Obama is pushing (again) for more funding for basic research. Is anybody going to listen this time? More | Follow @MarkHFierce

> The antibacterial drug developer Trius Therapeutics ($TSRX) is offering 8.6 million shares at a discount. Report

> Vanda Pharmaceuticals says its reaped some early efficacy data on four patients enrolled in its Phase III study for tasimelteon, a treatment designed to reset the body's biological clock. Release

Pharma News

@FiercePharma: $BMY earnings might have disappointed analysts--and Plavix is faltering--but newer meds grew--Bloomberg. Article | Follow @FiercePharma

> Abbott's round of 700 layoffs doesn't spare pharma. Story

> Ranbaxy faces 'groundbreaking' oversight with DoJ settlement. Item

> Bristol-Myers' Q4 shows growth in newer products. Report

Vaccines News

> Common chemicals threaten childhood vaccines. Story

> Researchers target multiple tumors in new cancer vaccine study. More

> Nanoparticles hijack immune response. Article

> Late-stage Galena vax offers hope for breast cancer patients. Story

Pharma Manufacturing News

> Owner arrested in Pakistani drug deaths cites Big Pharma conspiracy. Article

> Abbott includes manufacturing in 700 job cuts. News

> Warnings analysis spotlights analytics weakness. Story

> Merck 'program of projects' earns facility award. More

And Finally... A new study from Johns Hopkins shows that a doctor's weight could influence how they diagnose obesity in their patients. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.